Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants
© 2023. The Author(s)..
SARS-CoV-2 Omicron variants feature highly mutated spike proteins with extraordinary abilities in evading antibodies isolated earlier in the pandemic. Investigation of memory B cells from patients primarily with breakthrough infections with the Delta variant enables isolation of a number of neutralizing antibodies cross-reactive to heterologous variants of concern (VOCs) including Omicron variants (BA.1-BA.4). Structural studies identify altered complementarity determining region (CDR) amino acids and highly unusual heavy chain CDR2 insertions respectively in two representative cross-neutralizing antibodies-YB9-258 and YB13-292. These features are putatively introduced by somatic hypermutation and they are heavily involved in epitope recognition to broaden neutralization breadth. Previously, insertions/deletions were rarely reported for antiviral antibodies except for those induced by HIV-1 chronic infections. These data provide molecular mechanisms for cross-neutralization of heterologous SARS-CoV-2 variants by antibodies isolated from Delta variant infected patients with implications for future vaccination strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 24. Feb., Seite 1058 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Haisheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 28.02.2023 Date Revised 17.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-36761-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353350230 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353350230 | ||
| 003 | DE-627 | ||
| 005 | 20231226055806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-36761-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353350230 | ||
| 035 | |a (NLM)36828833 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Haisheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2023 | ||
| 500 | |a Date Revised 17.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a SARS-CoV-2 Omicron variants feature highly mutated spike proteins with extraordinary abilities in evading antibodies isolated earlier in the pandemic. Investigation of memory B cells from patients primarily with breakthrough infections with the Delta variant enables isolation of a number of neutralizing antibodies cross-reactive to heterologous variants of concern (VOCs) including Omicron variants (BA.1-BA.4). Structural studies identify altered complementarity determining region (CDR) amino acids and highly unusual heavy chain CDR2 insertions respectively in two representative cross-neutralizing antibodies-YB9-258 and YB13-292. These features are putatively introduced by somatic hypermutation and they are heavily involved in epitope recognition to broaden neutralization breadth. Previously, insertions/deletions were rarely reported for antiviral antibodies except for those induced by HIV-1 chronic infections. These data provide molecular mechanisms for cross-neutralization of heterologous SARS-CoV-2 variants by antibodies isolated from Delta variant infected patients with implications for future vaccination strategy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Liu, Banghui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yudi |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xijie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Haitao |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Xiaofang |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Caixia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yaping |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Peiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jingrong |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Pingqian |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Chengqian |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Guofang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaopan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Liliangzi |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xiumei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaojiao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chuanyu |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yaling |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Naibo |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qiuluan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zimu |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Mengzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qihong |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Rongjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xinwen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Longqi |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Fengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Ke, Bixia |e verfasserin |4 aut | |
| 700 | 1 | |a Ke, Changwen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Meiniang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xiaoping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 24. Feb., Seite 1058 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:24 |g month:02 |g pages:1058 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-36761-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 24 |c 02 |h 1058 | ||